基于心衰病史与肾素-血管紧张素系统拮抗剂使用的血管紧张素受体-脑啡肽酶抑制解读
PIONEER-HF 试验纳入 881 例射血分数≤40% 的急性失代偿性心衰稳定后患者,随机 1:1 院内启用沙库巴曲/缬沙坦(S/V)或依那普利。预设亚组分析显示,无论既往心衰病史(新发 vs. 慢性加重)或入院时是否使用 ACEI/ARB,S/V 均显著降低 NT-proBNP 且临床结局优于依那普利,不良事件发生率相当。
要点
- 无论新发或慢性加重心衰,S/V 较依那普利显著降低 NT-proBNP。
- 既往是否使用 ACEI/ARB 不影响 S/V 对心血管死亡或心衰再住院的获益。
- 各亚组中 S/V 与依那普利的不良事件发生率相当。
核心结论
- 在急性失代偿性心衰住院患者中,无论既往心衰病史或入院时 ACEI/ARB 使用情况,S/V 均安全耐受且较依那普利显著降低 NT-proBNP 并改善临床结局。
研究设计与样本
- PIONEER-HF 为前瞻性、多中心、双盲、随机临床试验,纳入 881 例射血分数≤40% 的急性失代偿性心衰稳定后患者,1:1 随机至院内启用 S/V(n=440)或依那普利(n=441)。
- 预设亚组分析基于既往心衰病史(新发 vs. 慢性加重)和入院时 ACEI/ARB 使用(是 vs. 否)。
主要发现
- 入组时 303 例(34%)为新发心衰,576 例(66%)为慢性加重心衰;421 例(48%)曾使用 ACEI/ARB,458 例(52%)未使用。
- 所有 4 个亚组 NT-proBNP 均显著下降(p < 0.001),且 S/V 组较依那普利组下降更显著(p < 0.001)。
- 既往心衰病史(p = 0.350)或 ACEI/ARB 使用(p = 0.880)与 S/V 对比依那普利对心血管死亡或心衰再住院的效应无交互作用。
- 所有 4 个亚组中 S/V 与依那普利的不良事件发生率相当。
临床怎么用
- 急性失代偿性心衰稳定后患者,无论既往心衰病史或是否使用 ACEI/ARB,均可考虑院内启用 S/V。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The PIONEER-HF (comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode) trial demonstrated the efficacy and safety of sacubitril/valsartan (S/V) in stabilized patients with acute decompensated heart failure (HF) and reduced ejection fraction. OBJECTIVES: The study sought to determine whether and how prior HF history and treatment with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) affected the results. METHODS: The PIONEER-HF trial was a prospective, multicenter, double-blind, randomized clinical trial enrolling 881 patients with an ejection fraction ≤40%. Patients were randomly assigned 1:1 to in-hospital initiation of S/V (n = 440) versus enalapril (n = 441). Pre-specified subgroup analyses were performed based on prior HF history (i.e., de novo HF vs. worsening chronic HF) and treatment with an ACE inhibitor or ARB (i.e., ACE inhibitor or ARB-yes vs. ACE inhibitor or ARB-no) at admission. RESULTS: At enrollment, 303 (34%) patients presented with de novo HF and 576 (66%) patients with worsening chronic HF. A total of 421 (48%) patients had been treated with an ACE inhibitor or ARB, while 458 (52%) had not been treated with an ACE inhibitor or ARB. N-terminal pro-B-type natriuretic peptide declined significantly in all 4 subgroups (p < 0.001), with greater decreases in the S/V versus the enalapril arm (p < 0.001). There was no interaction between prior HF history (p = 0.350) or ACE inhibitor or ARB treatment (p = 0.880) and the effect of S/V versus enalapril on cardiovascular death or rehospitalization for HF. The incidences of adverse events were comparable between S/V and enalapril across all 4 subgroups. CONCLUSIONS: Among patients admitted for acute decompensated HF, S/V was safe and well tolerated, led to a significantly greater reduction in N-terminal pro-B-type natriuretic peptide, and improved clinical outcomes compared with enalapril irrespective of previous HF history or ACE inhibitor or ARB treatment. (Comparison of Sacubitril/Valsartan Versus Enalapril on Effect of NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode [PIONEER-HF]; NCT02554890).
引用
- Ambrosy AP, Braunwald E, Morrow DA, et al. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. J Am Coll Cardiol. 2020. PMID: 32854838. doi:10.1016/j.jacc.2020.06.073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。